Farge-scale screening has led to the identfication of several exerimental compounds that have very potent intrinsic activit against coccid, but the lack of translation to in vivo efficacy has been a ujor hurdle in developing such leads into effective new drgs. We developed methods to explore the impact of oral availability and appropriate distribution in tissue, both of which are potentialy important fctors in the expression of activity in vivo. For the compounds that we examined, neither oral absorption nor distribution to the site of infection appeared to be the criial barrier to in vivo expresion of intrinsic anticoccd activity. Elucidation of the nature of additional factors that migt be involved could assist greatly in the identification of useful new anticoccidial agents.
Coccidiosis is a protozoal infection caused by intestinal parasites of the genus Eimeria. Control of coccidiosis is critical in intensively reared poultry, and there is a continual need for effective new anticoccidial agents.
Efficient, quantitative models for growth of poultry coccidia in tissue culture that are capable of detecting a majority of known anticoccidial drugs have been described (4, 8) . These models have been the key to large-scale, semiautomated screening of compounds to identify, new anticoccidial agents. A number of chemical classes that are highly potent in tissue culture can be identified; they sometimes have potencies that surpass those of commercial anticoccidial agents, but they are found to have no activity in vivo when administered by the route of choice for anticoccidial agents in the broiler industry, i.e., in feed (2, 7). This is a major stumbling block to the development of useful new agents.
Referring to their anticoccidial screening experiences, Hupe et al. (2) have stated that "lack of' in vivo activity of the drug despite conisiderable activity in tissue culture is a common observation in this system usually reflecting rapid metabolism by the host of the drug." Other potential explanations include the lack of oral availability and failure to reach the site of infection. We used an osmotic minipump infusion procedure to test whether continuous systemic administration would better reveal the intrinsic activity of a compound that may be poorly absorbed orally or rapidly cleared. This procedure enables efficient evaluation of a wide range of structures. For selected compounds, we also conducted a more intensive evaluation of the drug levels achieved at the site of infection in comparison with the potencies of the compounds in tissue culture.
For all compounds tested, we found that anticoccidial efficacy was essentially unchanged when we changed the route of administration from in feed to continuous parenteral infusion, arguing against the possibility that oral availability is a key barrier to expression of activity in vivo. Interestingly, for two experimental compounds, the drug concentrations achieved at the site of infection were greater than those required for activity in vitro. This implies that even when present in infected tissue at active concentrations, drug does not necessarily'gain access to the parasite that is developing in situ. Understanding of why this might be the case could be * Corresponding author. significant in the development of new classes of anticoccidial agents.
Test compounds. Decoquinate (Rhone-Poulenc Inc.) and 6-azauracil (Aldrich Chemical Company, Inc.) were obtained from commercial sources, and the other test compounds were prepared in Pfizer chemistry laboratories. Representatives of known anticoccidial classes included the 6-bromo,7-chloro-stenorol analog CP-60,9494 (9) and the aryl triazine 3-chloro-4-[2-chloro4-(4,5-dihydro-3,5-dioxo-1,2,4-tria zin-2(3H)-yl)-6-methylphenoxy]-N-ethyl-N-methylbenzenesulfonamide (CP-30,542 [3] ). The chemical structures of the two experimental compounds selected for the tissue concentration studies described here, compound I and compound III, are shown in Fig. 1 .
In vivo testing. Battery efficacy testing against Eimeria tenella was based on the drug screen described previously (1) . Medicated In vitro testing. The in vitro potencies of the study compounds were determined in an E. tenella tissue culture model with Madin-Darby bovine kidney cells as the host, and an enzyme-linked immunosorbent assay was performed as the endpoint, as described previously (4) . Results are expressed as the concentration that gave 50% inhibition of parasite development (IC50) without overt toxicity to the host cell. Each IC50 was determined by log-linear interpolation from a dose-response curve.
Drug levels in cecal mucosa. Levels of two esters (compounds I and III) and the corresponding acids generated by hydrolysis in vivo (compounds II and IV) were measured at the site of infection, i.e., the cecal mucosa. Tissue samples were obtained from groups of five chicks each that received medication in their feed for 24 h. Cecal contents were removed, the ceca were opened lengthwise, and the mucosal surface was washed with phosphate-buffered saline, and then the mucosa was separated from the muscularis by scraping. Samples of tissue scrapings (0.1 mg) were assayed following dilution with water (0.5 ml) and addition of the internal standard solution (0.05 to 0.2 ml) and acetonitrile (1 ml). The internal standard was a close structural analog of the compound of interest. Following centrifugation, the acetonitrile layer was removed and evaporated to dryness under N2 at 50°C. The residue was reconstituted in 0.5 ml of 0.1 M H3PO4 (pH 2.1) and was extracted with 5 ml of methylene chloride. Following centrifugation and removal of the lower aqueous layer, the organic layer was evaporated to dryness under N2 at 50°C. The resulting residue was reconstituted for analysis in 0.2 ml of methanol-water (50:50). The chromatographic system consisted of a 10-pm, 30 c The IC50 for 6-azauracil was 2.5 ,ug/ml (mean of four tests).
calculated from peak heights by comparison with a linear plot derived from the peak heights of calibration samples. These were prepared by adding known concentrations of each analyte to blank tissue samples collected from nonmedicated chickens. Extraction losses were corrected on the basis of the peak height of the internal standard. Assay performance was similar for each of the compounds. As a specific example, for compound IV calibration plots were linear from 20 to 100 p,g/g (?I = 0.991), and the lower limit of quantitation was 20 p,g/g (percent error, 7.2).
Efficacy model. Data for unmedicated control groups in the anticoccidial efficacy model are presented in Table 1 . Treatment with 6-azauracil was also included as a control to confirm that the model was capable of reliably detecting the activities of compounds with relatively low potencies, as might be expected of lead compounds. 6-Azauracil given in feed at 500 and 1,000 ppm produced highly reproducible lesion control.
Implanting minipumps. Subcutaneous infusion by minipump proved to be an efficient route of continuous parenteral administration of anticoccidial agents to chickens. Implantation of minipumps containing vehicle alone neither affected the course of disease in the efficacy model nor led to mortality or weight suppression in uninfected birds (data not shown), and no other side effects were observed. All pumps opened postmortem had emptied by the end of the 7-day treatment period, as expected.
Known anticoccidial agents. We tested three anticoccidial agents from known structure classes which have shown potent activity in vitro and by in-feed administration. Each agent demonstrated activity when it was administered by subcutaneous infusion ( Table 2 ). The active-dose ranges were comparable by both routes of administration, and the order of potency was the same in vitro, by infusion, and by in-feed administration, as follows: CP-60,949-4 > decoquinate > CP-30,542.
Experimental compounds. Data from a comparison of in-feed and parenteral administrations of compounds I and III are given in Table 2 . The compounds were selected for their in vitro potencies against E. tenella from among 30,000 compounds screened. Despite having in vitro potency in the same range as commercial anticoccidial agents, both compounds lacked in vivo activity by both the in-feed and parenteral routes. An additional 16 compounds (IC50s, <0.1 to 34 ng/ml) were compared by in-feed (given at a dose of 500 ppm) and minipump (given at doses of 0.57 to 2.29 mg/day) administrations, with the same lack of significant efficacy by VOL. 36, 1992 on November 6, 2017 by guest http://aac.asm.org/
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ANTiMICROB. AoENrrs CHEMOTHER. either route. The compounds were structurally unrelated to each other and to commercial anticoccidial agents. Additionally, a single daily intraperitoneal injection of 1, 5, and 10 mg of compound I in saline per bird from day -1 to day 6 of infection did not lead to anticoccidial efficacy (data not shown). Drug levels in cecal mucosa. Compounds I and III were selected for study of levels of drug in tissue at the site of infection. Both compounds showed potent in vitro anticoccidial activity as esters, but they were less potent as the corresponding acids. The results in Table 3 confirm that hydrolysis of the esters took place in vivo. When the compounds were administered in feed, the concentrations of compound I achieved in the cecal mucosa were 150-fold greater than the IC50, and compound IV was present at concentrations 4-fold greater than its IC50.
By empirical screening against E. teneUa, many compounds that have in vitro potency equivalent to or greater than those of commercial agents (IC50 in the nanogram-permilliliter range or below) have been uncovered. All such compounds included in this study lacked oral activity, de- spite dosing at levels in feed that were 20-to 200-fold higher than those required for the activities of commercial agents with comparable in vitro potencies. This is a general problem in the discovery of new anticoccidials agents; for example, (2) . The lack of in vivo activity of the compounds that we tested does not appear to be a simple problem of lack of oral availability. None of the compounds showed activity at the highest levels tested by parenteral infusion, even though dose levels given by minipump were in the same range as those required for the activities of commercial agents with comparable in vitro potencies. Rapid inactivation or clearance in vivo is another possibility, and to examine this, we measured the concentrations of two compounds that were clearly susceptible to metabolism achieved at the tissue site of infection. We found that during in-feed medication, compounds I and IV achieved levels in cecal mucosa considerably higher than the IC50s, yet no efficacy was observed.
From our results, we conclude that in vitro anticoccidial potency combined with levels in tissue greater than the IC50 is not sufficient for in vivo activity. If we could gain insight into the other factors that are involved, then a large selection of very potent structure classes that could potentially give rise to new anticoccidial drugs would be available. A possibility that could be explored further is that the net uptake of compound into host cells or the subcellular distribution of compounds differs between the natural host cell (chicken intestinal epithelial cells) and the artificial host cell used in tissue culture models (bovine kidney cells) or that the infection takes place in a different subcellular location. To this point, apart from kidney cells, no cell lines are available as a host for E. teneUla.
Continuous infusion was found to be a better method of parenteral administration than subcutaneous injection for a related sporozoan parasite, in this case, a malaria model in primates: desferrioxamine was active when given by minipump, but it was inactive when given by injection (5). For experimental purposes, subcutaneous infusion by osmotic minipump is an efficient way of continuously administering anticoccidial agents parenterally for comparison with in-feed medication. Uneven drug levels and the stress to the birds of frequent handling and injection are avoided. The three known agents included in the present study that were active in feed were also active when administered by minipump. The systemic activities of anticoccidial agents by cecal ligation (10) and injection have been demonstrated previously (6) . In that study, the parenteral route was effective on more stages of the life cycle than the in-feed route was. The availability of the minipump infusion technique described here will enable continued efficient evaluation of experimental compounds for their in vivo activities by the parenteral route and should be particularly useful in testing agents expected to be poorly absorbed or destroyed in the gut.
